The goal of this project was to elucidate the role of the homeodomain transcription factor family in terminal fate specification of an entire nervous system. In pursuit of this, I systematically identified the expression patterns of all 102 homeobox genes in the L4/adult stage C. elegans nervous system at a single-neuron resolution. This involved acquiring and/or generating high-quality fluorescent reporter reagents to tag all 102 homeodomain transcription factor proteins. Then, analyzing the expression of those reagents using a novel tool for whole nervous system identification in C. elegans, called NeuroPAL. The resulting expression atlas is the first complete picture of the homeobox family in any nervous system. It allowed the identification of new terminal selector proteins, including ceh-8, ceh-32, and ceh-31, in various neuron types and will continue to serve as a guide for future terminal selector identification across the nervous system. We discovered that every neuron type, and many subtypes, of the C. elegans nervous system express a completely unique set of homeodomain transcription factors. This unique expression code, along with the scores of homeodomain terminal selectors, suggests the possibility that every C. elegans neuron type is specified by a homeodomain terminal selector. We further probed the importance of the homeobox family in neuron specification by comparing its expression pattern with other transcription factor families. This necessitated high-quality data for the other major transcription factor families, bHLH, ZF, AtHook, bZip, and NHR, in every C. elegans neuron type. In collaboration with the labs of David Miller III at Vanderbilt and Marc Hammarlund at Yale, we used single cell RNA sequencing (scRNA-Seq) to molecularly profile all neuron types of the L4 stage C. elegans nervous system. We found that our homeodomain protein atlas was recapitulated fairly well in the scRNA-Seq data when thresholded and determined that the homeodomain transcription factor family is not alone in generating unique expression profiles for every neuron type. Two larger transcription factor families, ZF and NHR, are also uniquely expressed in each neuron identity. Instead, we found that the homeodomain transcription factor family is set apart from other families by their distinctly sparse expression across the nervous system at comparatively high levels. These expression patterns along with the numerous examples of functional homeodomain terminal selectors suggest that the family is an underlying theme in neuronal specification. We further extended this analysis to available scRNA-Seq datasets in the mouse nervous system and noted select commonalities in homeobox family expression across organisms. In all, this study shows yet again that analyzing homeodomain transcription factors leads to fruitful insights on organismal development. We found that the complexity of the C. elegans nervous system can be categorized and largely specified by a single family of transcription factors, building on previous studies of their importance in neuronal function.

Colon cancer is one of the most common cancers in both the United States (US) and throughout the world. Over the last 30 years, despite the development of multiple classes of effective anti-tumor agents, colon cancer has consistently remained the second leading cause of mortality amongst all cancers and is today responsible for over 50,000 deaths a year in the US alone. Among the greatest challenges to the successful treatment of colon cancer is its heterogeneity in terms of drug-sensitivity, whereby it is often difficult to identify which patients will benefit from a specific class of anti-tumor agents before treatment has begun. It is therefore imperative to identify predictive biomarkers that can be leveraged to distinguish which colon tumors are most likely to respond to individual anti-cancer drugs. This will help develop new therapeutic algorithms that can maximize patient survival by rapidly matching individual patients with the specific treatment combinations that are most likely to benefit them as well as sparing them the toxicities from drugs that would be ineffective. Previous studies have reported that human colon carcinomas lacking expression of the caudal-type homeobox 2 (CDX2) transcription factor can be leveraged as a predictor of benefit from adjuvant chemotherapy containing 5-fluorouracil (5-FU). Lack of CDX2 expression associates with microsatellite instability (MSI), as well as several histopathological and molecular features that associate with exceptionally poor prognosis such as poor differentiation, lympho-vascular invasion, and BRAF mutation. However, the molecular mechanisms linking lack of CDX2 expression with increased drug sensitivity are currently unknown. In the first section of this study, we conducted a high throughput screen (HTS) aimed at identifying clinically approved anti-tumor drugs that display selective activity against colon carcinomas lacking CDX2 expression (CDX2-negative). The results of our screening, which compared an isogenic pair of CDX2+/+ and CDX2-/- cell lines generated by genetic inactivation of CDX2 using CRISPR/Cas9 constructs, revealed that CDX2-negative colon cancer cells display increased sensitivity to anti-tumor drugs that are substrates of the ATP binding cassette sub-family B member 1 (ABCB1) transporter. ABCB1 is a drug-efflux protein known for its capacity to extrude multiple classes of anti-tumor agents from the cytoplasm, therefore contributing to drug-resistance in cancer cells. Importantly, analysis of CDX2 and ABCB1 expression in two independent gene-expression databases (NCBI-GEO: n=2115; TCGA: n=478) revealed that a lack of CDX2 expression is invariably associated with lack of ABCB1 expression in human primary colon carcinomas. Furthermore, our molecular studies revealed that forced expression of CDX2 in human CDX2-negative colon cancer cells was capable of inducing expression of ABCB1, while genetic inactivation of CDX2 in human CDX2-positive cancer cells using CRISPR/Cas9 constructs resulted in loss of ABCB1 expression, thus establishing CDX2 as a direct mechanistic regulator of ABCB1 expression. Amongst all of the anti-tumor drugs identified as being ABCB1 substrates with preferential activity against CDX2-negative colon cancer cells, we observed that paclitaxel was the FDA-approved drug with the greatest degree of selectivity with a 10-fold difference in IC50. When tested in vivo against a collection of human patient derived xenograft (PDX) lines representative of both CDX2-negative and CDX2-positive colon carcinomas, paclitaxel displayed selective activity against CDX2-negative models, often inducing volumetric regression of established lesions. Our study, therefore, identified paclitaxel as a clinically approved anti-tumor agent that should be investigated for use in the treatment of CDX2-negative colon carcinomas. In the second portion of our study, we sought to conduct a preliminary evaluation of the possibility of using immune checkpoint inhibitors (ICIs) for the treatment of CDX2-negative colon carcinomas. ICIs have been shown to display substantial anti-tumor activity against colon carcinomas with microsatellite instability (MSI) and against epithelial malignancies over-expressing the immune-suppressive molecule PD-L1/CD274. Because CDX2-negative tumors are enriched for MSI and high levels of PD-L1/CD274, they are predicted to include a subgroup that is responsive to ICIs. However, not all MSI tumors respond to ICIs and, contrary to the majority of MSI tumors, the subgroup of MSI tumors characterized by a CDX2-negative phenotype is often associated with poor prognosis. Because the clinical activity of ICIs is dependent upon expression of class-I HLA molecules by tumor cells, we decided to evaluate whether CDX2-negative tumors were associated with inactivating mutations in class-I HLA genes. Our attention focused on a highly conserved poly-cytosine repeat region in the coding sequence of HLA-A (c.621_627) and HLA-B (c.621_626) genes. Because this sequence fulfilled the molecular definition of microsatellite, we predicted it to be highly susceptible to frameshift mutations (insertions or deletions) in MSI colon tumors. Indeed, a search across three independent genetic databases (TCGA, COSMIC, EBI) confirmed that this highly conserved poly-cytosine repeat region was targeted by recurrent and deleterious mutations in at least one HLA-A or HLA-B allele of at least 13% (n=21/156) of human MSI colon tumors, as compared to 0.3% (n=2/770) of human colon tumors with a microsatellite stable (MSS) phenotype (p<0.0001). Among tumors assessable for CDX2 expression, this specific type of class-I HLA mutations was more frequent among CDX2-negative (12%; n=6/49) as compared to CDX2-positive (1.5%; n=5/340) colon tumors (p<0.001), but was similar within MSI CDX2-negative (21%; n=6/28) and MSI CDX2-positive (17%; n=5/30) subgroups. In summary, this work achieved two main results: 1) it identified paclitaxel, a clinically approved anti-tumor drug, as a new treatment option for patients with CDX2-negative colon cancers, which represents an extremely aggressive subgroup of colorectal malignancies; 2) it revealed that, in human MSI colon tumors, class-I HLA genes are prone to recurrent frameshift mutations in a genomic hotspot, mutations that are likely to associate with tumor resistance to ICIs and that they are therefore likely to represent a new class of actionable predictive biomarkers for both MSI and CDX2-negative colon carcinomas. These findings will help advance our understanding of colon cancer biology, and hopefully improve treatment algorithms for the clinical management of colon cancer patients.

Thrombocytes are functional equivalents of mammalian platelets and also possess megakaryocyte features. It has been shown earlier that hox genes play a role in megakaryocyte development. Our earlier microarray analysis showed five hox genes, hoxa10b, hoxb2a, hoxc5a, hoxc11b and hoxd3a, were upregulated in zebrafish thrombocytes. However, there is no comprehensive study of genome wide scan of all the hox genes playing a role in megakaryopoiesis. I first measured the expression levels of each of these hox genes in young and mature thrombocytes and observed that all the above hox genes except hoxc11b were expressed equally in both populations of thrombocytes. hoxc11b was expressed only in young thrombocytes and not in mature thrombocytes. The goals of my study were to comprehensively knockdown hox genes and identify the specific hox genes involved in the development of thrombocytes in zebrafish. However, the existing vivo-morpholino knockdown technology was not capable of performing such genome-wide knockdowns. Therefore, I developed a novel cost- effective knockdown method by designing an antisense oligonucleotides against the target mRNA and piggybacking with standard control morpholino to silence the gene of interest. Also, to perform knockdowns of the hox genes and test for the number of thrombocytes, the available techniques were both cumbersome or required breeding and production of fish where thrombocytes are GFP labeled. Therefore, I established a flow cytometry based method of counting the number of thrombocytes. I used mepacrine to fluorescently label the blood cells and used the white cell fraction. Standard antisense oligonucleotide designed to the central portion of each of the target hox mRNAs, was piggybacked by a control morpholino and intravenously injected into the adult zebrafish. The thrombocyte count was measured 48 hours post injection. In this study, I found that the knockdown of hoxc11b resulted in increased number of thrombocytes and knockdown of hoxa10b, hoxb2a, hoxc5a, and hoxd3a showed reduction in the thrombocyte counts. I then screened the other 47 hox genes in the zebrafish genome using flow sorting method and found that knockdown of hoxa9a and hoxb1a also resulted in decreased thrombocyte number. Further, I used the dye DiI, which labels only young thrombocytes at specific concentrations and observed that the knockdown of hoxa10b, hoxb2a, hoxc5a, hoxd3a, hoxa9a and hoxb1a, lead to a decrease in young thrombocytes; whereas hoxc11b knockdown lead to increase in number of young thrombocytes. Using bromodeoxyuridine, I also showed that there is increase in release of young thrombocytes into peripheral circulation in hoxc11b knockdown fish which suggests that hoxc11b significantly promotes cell proliferation rather effecting apoptosis. In conclusion, I found six hox genes that are positive regulators and one hox gene is a negative regulator for thrombocyte development.

Final publication is available at http://www.plosgenetics.org/article/related/info%3Adoi%2F10.1371%2Fjournal.pgen.1005802 / 京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19627号 / 医博第4134号 / 新制||医||1016(附属図書館) / 32663 / 京都大学大学院医学研究科医学専攻 / (主査)教授 萩原 正敏, 教授 松田 秀一, 教授 瀬原 淳子 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

The specification and development of nervous system diversity is a driving question in the field of Neurobiology. The overarching goals of the projects described in this thesis are to describe tools to aid in the description of nervous system development and to show the use of the described tools to study nervous system development in the nematode Caenorhabditis elegans. The first chapter of this thesis describes a complete map of the male C. elegans nervous system using a tool developed in the lab to uniquely label all neurons in the C. elegans nervous system, NeuroPAL. The second chapter of this thesis largely focuses on a well-studied homeobox gene, unc-86, and its role in fate transformations in dopaminergic and GABAergic neuron types. These two seemingly disparate projects are united in their effort to investigate nervous system development and neuronal fate determination. NeuroPAL is a multicolor transgene that uniquely labels all neurons of the C. elegans hermaphrodite nervous system and here I show it can be used to disambiguate all 93 neurons of the male-specific nervous system. I demonstrate the wide utility of NeuroPAL to visualize and characterize numerous features of the male-specific nervous system, including mapping the expression of gfp-tagged reporter genes and neuron fate analysis. NeuroPAL can be used in combination with any gfp-tagged reporters to unambiguously map the expression of any gene of interest in the male, or hermaphrodite, nervous system. Furthermore, NeuroPAL is used in mutants of several developmental patterning genes to confirm previously described defects in neuronal identity acquisition. Additionally, I show that NeuroPAL can be used to uncover novel neuronal fate losses and identity transformations in these mutants because of the unique labeling of every neuron. Lastly, we show that even though the male-specific neurons are generated throughout all four larval stages, the neurons only terminally differentiate in the fourth and final larval stage, termed ‘just-in-time’ differentiation. In the second part of this thesis, I describe a few examples of mutant analysis of homeobox gene family members and describe their function in the C. elegans nervous system. I focus largely on a couple potential examples of homeotic fate transformations in mutants of the POU homeobox gene, unc-86. In unc-86 mutants, I describe the ectopic expression of multiple GABAergic terminal identity features in one cell in the head of C. elegans. I raise the hypothesis that this cell may be a transformation of a non-GABAergic ring interneuron, RIH, into that of its GABAergic sister cell, AVL, in unc-86 mutants. While ectopic dopaminergic neurons were previously described in unc-86 mutants, I expand the study to show the ectopic expression of all dopaminergic synthesis and packaging genes. I show support that all non-dopaminergic anterior deirid neurons, ADA, AIZ, FLP, and RMG, lose the expression of some of their wild type terminal fate genes and transform to a fate like that of their dopaminergic sister cell, ADE, as assessed by NeuroPAL expression. Taken together, these studies describe tools and methods for studying nervous system development as well as describe many examples of cell fate transformations.

When it comes to cell types, the cerebral cortex is one of the most diverse regions in the mammalian brain. Mouse cortical neurons are generated during development from radial glial cells (RGCs). But how these stem cells generate the different neuronal subtypes is still an open question. In the adult, transcription factors, specially homeobox genes, have been identified as determinants of neuronal types throughout the animal kingdom. Thus, in this study, we hypothesise that different subpopulations of neuronal progenitors (RGCs) give rise to subsequent subtypes of neurons in the cortex, and these populations can be defined by homeobox gene expression. Starting from a scRNA- seq analysis, we identified differentially expressed genes across different progenitor populations in the developing cortex: Adnp2, Homez and Hmbox1. We characterised their mRNA and protein expression across cortical layers in postnatal mice and found that these genes are also differentially expressed among layers. We also find discordances between scRNA-seq data, mRNA expression, and protein expression data that could indicate specific post-transcriptional regulation of these genes. Altogether, these results point to a role of homeobox genes in neuronal identity.

Regulation of expression DLX1 gene, whose elevated levels are detected in patients with acute myeloid leukemia with FLT3-ITD mutations, is not still completely explored topic. The first aim of this study was to determine which selected signaling pathways regulate gene expression of DLX1. ERK a JNK pathways were selected by using qRT-PCR and western blot. These pathways cause activation of the transcription factor AP-1 subunits, the AP-1 putative promoter binding site was identified also in the promoter of the DLX1 gene. The second aim of this study was to test the hypothesis on the regulation of gene expression of DLX1 (via ERK/JNK pathway) through AP-1 binding site on the promoter. Dual luciferase assay using luminescent luciferase activity was performed to test this hypothesis. Gene of the luciferase is contained in the used luciferase vector. The short and the long part of the DLX1 promoter (around AP-1 site) were inserted before the gene of the luciferase in the constructs used in this method. The results of this study indicate that the regulation of gene expression through AP-1 promoter binding site is important but not sufficient part of the regulatory cascade running through ERK and JNK pathway. There must be another transcription factors activated by ERK1/2 kinase which are probably also involved in...

The ParaHox cluster is the evolutionary sister of the Hox cluster. Like the Hox cluster, the ParaHox cluster is subject to complex regulatory phenomena such as collinearity. Despite the breakup of the ParaHox cluster within many animals, intact and collinear clusters have now been discovered within the chordate phyla in amphioxus and the vertebrates, and more recently within the hemichordates and echinoderms. The archetypal ParaHox cluster of amphioxus places it in a unique position in which to examine the regulatory mechanisms controlling ParaHox gene expression within the last common ancestor of chordates, and perhaps even the wider Deuterostomia. In this thesis, the genomic and regulatory landscape of the amphioxus ParaHox cluster is characterised in detail. New genomic and transcriptomic resources are used to better characterise the B.floridae ParaHox cluster and surrounding genomic region, and conserved non-coding regions and regulatory motifs are identified across the ParaHox cluster of three species of amphioxus. In conjunction with this, the impact of retrotransposition upon the ParaHox cluster is examined and analyses of transposable elements and the AmphiSCP1 retrogene reveal that the ParaHox cluster may be more insulated from outside influence than previously thought. Finally, the detailed analyses of a regulatory element upstream of AmphiGsx reveals conserved mechanisms regulating Gsx CNS expression within the chordates, and TCF/Lef is likely a direct regulator of AmphiGsx within the CNS. The work in this thesis makes use of new genomic and transcriptomic resources available for amphioxus to better characterise the genomic and regulatory landscape of the amphioxus ParaHox cluster, serving as a basis for the improved identification and characterisation of functional regulatory elements and conserved regulatory mechanisms. This work also highlights the potential of Ciona intestinalis as a ‘living test tube' to allow the detailed characterisation of amphioxus ParaHox regulatory elements.

Os genes homeobox atuam como reguladores da morfogênese e diferenciação celular embrionária, portanto, é evidente a possibilidade de sua expressão anormal estar presente na progressão de tumores. Estudos preliminares em nosso laboratório verificaram a participação de alguns genes homeobox em carcinoma epidermóide de boca (CEB). Este trabalho teve como objetivo avaliar a amplificação, expressão e o perfil de metilação dos genes HOXA5, HOXA7, HOXA9, HOXB5, HOXB13, HOXC12 em linhagem celular derivadas de CEB e tecidos frescos tumoral e não-tumoral. Além disso, verificar o efeito da desmetilação na expressão gênica de linhagens celulares que apresentaram genes 100% metilados e a participação das enzimas responsáveis pela metilação do DNA, bem como a expressão das DNAmetiltransferases (DNMT) nos tumores. A análise de amplificação do DNA e expressão de mRNA foi realizada por qRT-PCR. O perfil de metilação foi avaliada pelo sistema PCR Array e a análise proteica das DNMT1, DNMT3a, DNMT3b e HOXA9 foi verificada por meio de reações imunohistoquímicas. As linhagens celulares SCC4 e SCC9 foram utilizadas para análise de desmetilação com 5-aza-2\'-deoxicitidina e a linhagem SCC4 para avaliar os efeitos do aumento de expressão do HOXA9, na proliferação celular por imunocitoquimica para Ki67, migração celular por transwell e apoptose pela avaliação de células positivas no ensaio de TUNEL. Na comparação entre os grupos, o gene HOXA5 apresentou-se amplificado na margem em relação ao tumor; o HOXA9 apresentou nível de metilação aumentada no tumor; o HOXB5 com amplificação maior na margem, com nível de expressão do mRNA aumentada nos tumores, e nível de metilação do tumor maior em relação a margem, sendo correlacionada com menor sobrevida; HOXB13 se apresentou amplificado no tumor em relação a margem, e com nível de metilação maior nos tumores e, HOXC12 com níveis de metilação maior nos tumores em relação a margem. É interessante, que os mesmos genes que tiveram níveis de metilação aumentados nos tumores em relação a margem, também estavam 100% metilados nas linhagens celulares SCC4 e SCC9 e tiveram sua expressão restaurada após o tratamento com 5-aza-2´-deoxicitina. Na avaliação do nível de expressão das DNMTs nos tumores, a DNMT3b apresentou-se com níveis aumentados em relação a DNMT1 e DNMT3a, e quando avaliado em nível proteico, a DNMT3a pode ser correlacionada com melhor sobrevida. O aumento da expressão do gene HOXA9 mostrou diminuição da migração celular, porém não alterou a proliferação e apoptose celular. A expressão proteica não apresentou correlação com parâmetros clínicos. Em conclusão, os resultados mostram que os genes homeobox estudados estão pouco metilados nas linhagens celulares e em tecidos de CEB. A amplificação desses genes não é um evento frequente. O gene HOXA9 é pouco expresso no tumor, e o aumento da sua expressão em linhagens celulares diminui a migração celular. / Homeobox genes are important as morphogenetic and embrionary cellular differentiation regulators, therefore there is basis for their abnormal expression in tumor progression. Preliminary studies in our laboratory have shown that homeobox genes are dysregulated in oral squamous cell carcinoma (OSCC). This study evaluates the genomic amplification, mRNA expression and methylation status of HOXA5, HOXA7, HOXA9, HOXB5, HOXB13, HOXC12 in squamous cell carcinoma derived cell lines, and fresh tumor tissue. Also, analyzes the demethylation effect in gene expression of cell lines with genes showing 100% methylation, and the participation of enzymes responsible for DNA methylation, DNAmetiltransferases (DNMT), in gene and protein expression in tumors. DNA amplification and mRNA expression was analyzed by qRT-PCR. The methylation profile was evaluated by PCR Array System and DNMT1, DNMT3a, DNMT3b and HOXA9 protein expression was verified by immunohistochemistry. SCC4 and SCC9 cell lines were submitted to 5-aza-2\'-deoxycytidine for demethylation analysis. SCC4 cell lineage was analyzed by immunocytochemistry for Ki67, cell migration by transwell and apoptosis by TUNEL test after increased expression of HOXA9. HOXA5 gene was amplified in the adjacent margin when compared with the tumor; HOXA9 showed increased level of methylation in tumor; HOXB5 showed amplification in the margin, increased mRNA expression in tumors, increased methylation level and was correlated with decreased survival; HOXB13 was amplified in tumor samples when compared to the margins and also higher methylation level in tumors; and HOXC12 also showed increased methylation levels in tumors when compared to margin. Interestingly, the same genes with increased methylation levels in tumors, were also 100% methylated in cell lines SCC4 and SCC9. The expression of these gens was restored after treatment with 5-aza-2\'-deoxycytidine. DNMT3b presented higher levels of protein expression relative to DNMT1 and DNMT3a. DNMT3a protein expression was correlated with improved survival. SCC4 cells overexpressing HOXA9 gene showed decreased cell migration, with no effect on cell proliferation and apoptosis. HOXA9 protein expression was not correlated with clinical parameters. In conclusion, the results shows that homeobox genes are methylated in some OSCC cell lines and tissues. Amplification of these genes is not a frequent event. HOXA9 gene has low expression in OSCC, and when overexpressed in cell lines decreases cell migration.

The heterogeneous nature of acute myeloid leukemia (AML) worsens the results of patients treated with standard therapy. Understanding the processes of leukemogenesis can contribute to identification of more appropriate treatment. Family of DLX genes (Distal-less homeobox), belonging to the homeobox genes, are associated with haematological malignancies and solid tumors. In the analysis of expression data, the low level of the DLX1 gene was associated with a worse prognosis of patients with AML. In this work we studied phenotypic changes of cell lines with different expression of the DLX1 gene. We silenced the DLX1 gene in AML cell line (sh cells) and compared it to the parental line with higher expression of DLX1 (NSC cells). By cell cycle analysis and apoptosis assays in vitro and in vivo, we have observed the arrest of sh cells in the G0 phase and a lower number of apoptotic cells. Differences were found when measuring the absolute number of cells in time. In in vitro conditions there were less sh cells, in in vivo environment there was significantly higher number of sh cells engrafted in comparison to NSC cells. Further results have shown that sh cells have lower levels of pro-apoptotic proteins and exhibit a higher level of TGF-β targeting PAI-1 gene that activates replicative senescence. We...